Floatz logo

Lifileucel

Dedifferentiated Chondrosarcoma

M.D. Anderson Cancer CenterCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Dedifferentiated Chondrosarcoma cohort.

Asset / SponsorPhaseRating
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC
Fludarabine
M.D. Anderson Cancer Center
Phase 2CCC
Ipilimumab
M.D. Anderson Cancer Center
Phase 2CCC
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2CCC
Nivolumab
M.D. Anderson Cancer Center
Phase 2CCC

Same molecule, other indications

Lifileucel is also rated in:

melanomaDormant
BB
Indicative ·
66 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
66 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →